
Press Release|Articles|December 3, 2024
Camber Pharmaceuticals Announces Addition of Decitabine for Injection
Listen
0:00 / 0:00
Key Takeaways
- Decitabine for Injection targets adult patients with myelodysplastic syndromes, including various subtypes and chronic myelomonocytic leukemia.
- The product is offered in a 50 mg single-dose vial, enhancing treatment accessibility.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Decitabine for Injection.
Decitabine for Injection is indicated for treatment of:
- adult patients with myelodysplastic syndromes (MDS)
- de novo and secondary MDS of all French-American British subtypes
- refractory anemia with excess blasts
- chronic myelomonocytic leukemia
Decitabine for Injection is available in a 50 mg Single-Dose Vial.
To find out more information on Decitabine for Injection please visit:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
2
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
3
Ribociclib Plus Fulvestrant Shows Strong PFS and OS Benefits in Patients With Invasive Lobular Carcinoma
4
FDA Approves First At-Home Treatment Device for Depression
5
















































































































































































































